PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Phase 1

Completed

• Conditions: Neoplasm Metastasis; Neoplasm Recurrence
• Interventions: Drug: PG2

• Registration Number: NCT01696565
• Lead Sponsor: PhytoHealth Corporation

Brief Summary

The objectives of this Phase I/II study are:

1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II.

2. To evaluate the hematopoietic and immunological responses after administering of PG2. Primarily to study the biological response of PG2, defined as WBC count in this study, and secondarily to study the immunological factors, IL-2, IL-6, TGF-beta, and G-CSF.

Detailed Description

This study is the first step for PG2 clinical development in Taiwan in order to further establish its safety and efficacy profile and to build the basis for larger trials.

Study Timeline

• Study Start: 2001-12
• Primary Completion: 2003-10
• Study Completion: 2003-10
• Study First Submitted: 2011-03-28
• Study First Submitted QC: 2012-09-27
• Study First Posted: 2012-10-01
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-04
• Last Update Posted: 2024-11-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Patient must have malignancy with metastatic or recurrent diseases.
• Patient must have a minimum of thirteen days period elapsed from any previous chemotherapy or radiotherapy and all treatment-related toxicities subsided.
• Patient must have at least 2 courses of chemotherapy treatment left, and a minimum of 13 days between the administration of the last dose of the chemotherapy with PG2 and the start of the next course of chemotherapy.
• Performance status is 0-2 by ECOG scale.
• Patient's compliance and geographic proximity that allow adequate follow up.
• Adequate bone marrow function before the chemotherapy
• Adequate liver and renal function before the chemotherapy
• Written informed consent from patients
• Woman with childbearing potential should use contraception method through the whole PG2 treatment course.
• After the previous course of chemotherapy, the nadir of WBC dropped between 1000 to 3000/ mm3 (for phase II only).

Exclusion Criteria

• PG2 skin test is positive.
• Active infection
• Breast feeding
• Prior radiotherapy more than 30% of the bone marrow involved.
• Pregnant woman
• Bone marrow transplantation or brain disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
250 mg/day Treatment Arm	PG2	250 mg/day PG2 treatment continuously for 7 days
500 mg/day Treatment Arm	PG2	500 mg/day PG2 treatment continuously for 7 days
125 mg/day Treatment Arm	PG2	125 mg/day PG2 treatment continuously for 7 days

Primary Outcome Measures

Name	Time	Method
Phase I: To find the maximum tolerated dose (MTD) or the highest tolerated dose (HTD) as the study dose of PG2; Phase II: To use the study dose and assess the WBC level of PG2	within 14 days of each chemotherapy cycle	For phase I study, the primary endpoint is to determine a safe dosage of PG2 by the dose escalation design.; For phase II study, the primary endpoint is to compare the WBC level between PG2 plus chemotherapy and chemotherapy alone.

Secondary Outcome Measures

Name	Time	Method
Phase II: To use the study dose to assess the hematopoietic and immunological cytokine levels	within 14 days of each chemotherapy cycle	For phase II study, the secondary endpoint is to compare the levels of IL-2, IL-6, TGF-beta and G-CSF between PG2 plus chemotherapy and chemotherapy alone.

Trial Locations

Locations (1)

Tri-Service General Hospital; 🇨🇳 Taipei, Taiwan